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Abstract
Aims/hypothesis We studied the associations of size at birth
and prematurity with type 2 diabetes, insulin sensitivity and
beta cell function in the Danish population-based Inter99
study (ClinicalTrials.gov NCT00289237).
Methods Information about size at birth and prematurity
was identified from original midwife records in 4,744
middle-aged Danes. Type 2 diabetes status, insulin sensitivity
(Matsuda index) and beta cell function (disposition
index) were assessed using a 75 g oral glucose tolerance
test. Participants born prematurely were compared with
a group of at-term participants born small for gestational
age.
Results An increase in birthweight of 1 kg was associated
with a 51% (OR 0.49, 95% CI 0.35–0.69) reduced risk of
type 2 diabetes. Ponderal index, reflecting thinness at birth,
was associated with type 2 diabetes to the same extent as
birthweight. The prevalence of type 2 diabetes was
increased to a similar degree in participants born prema-
turely and participants born small for gestational age,
although the former had a higher ponderal index at birth.
In addition, birthweight z-scores, reflecting fetal growth
rate, were unrelated to the risk of type 2 diabetes and to
other measures of glucose regulation in participants born
prematurely. While low birthweight was inversely associ-
ated with insulin sensitivity and beta cell function,
prematurity was associated solely with decreased insulin
sensitivity.
Conclusions/interpretation While the association between
birthweight and risk of type 2 diabetes is mediated via
combined effects on beta cell function and insulin sensitivity,
prematurity seems to influence risk of type 2 diabetes via
attenuated insulin sensitivity only and independently of fetal
growth rates.
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Low birthweight has previously been associated with type 2
diabetes [1, 2]. However, only few studies have examined
this association in a random sample of the population and
used an OGTT to diagnose type 2 diabetes. Reduced insulin
sensitivity has been reported to be a mediator between low
birthweight and type 2 diabetes [2, 3], while beta cell
dysfunction has been associated with low birthweight in
some [1] but not all studies [2].
Beside low birthweight, prematurity as such has been
associated with reduced insulin sensitivity in young patients
[4]. A recent Swedish register-based study reported that
prematurity was associated with an increased risk of type 2
diabetes independently of birthweight [5].
We aimed to examine the associations between both size
at birth and prematurity, and the risk of type 2 diabetes in a
Danish study sample. We also examined the extent to which
birthweight and/or prematurity are associated with insulin
sensitivity and/or beta cell function.
Methods
Study background The Inter99 study is a Danish intervention
study aimed at reducing the incidence of ischaemic heart
disease and type 2 diabetes [6] (www.Inter99.dk, accessed 7
September 2010). From a population-based sample
(n=61,301) of 30- to 60-year-old individuals, a random
sample of 13,016 was invited. The participation rate was
52.5% (n=6,784). We used data from the baseline examina-
tions, which were performed from 1999 to 2001. Participants
gave written informed consent prior to inclusion. The
protocol was in accordance with the Helsinki Declaration,
approved by the local ethics committee (KA98155) and
registered with ClinicalTrials.gov (NCT00289237).
Participants completed a self-administered questionnaire on
health, socioeconomic factors, lifestyle and maternal/paternal
diabetes status (yes/no/unknown). Lifestyle variables included
physical activity, diet, alcohol consumption and smoking.
After an overnight fast, a 75 g OGTTwas performed. Venous
samples for measurement of plasma glucose and serum insulin
concentrations were taken at 0, 30 and 120 min and analysed
as previously described [6]. Type 2 diabetes was diagnosed
according to the WHO 1999 criteria [7].
Midwife records of 4,744 participants were identified as
previously described [8]. Ponderal index, i.e. birthweight
(kg)/length(m3), was calculated as a measure of infant body
composition. We included 4,644 participants born as
singletons and without type 1 diabetes in this study.
Prematurity Participants born prematurely (before week 37)
were compared with a group of singletons born at term
(weeks 37–42) and matched for birthweight; this group was
referred to as small for gestational age (SGA). The remaining
participants born at term were considered appropriate for
gestational age. Detailed information on gestational age was
available in 363 of the 443 participants born prematurely and
fetal growth rates were assessed using birthweight z-scores,
calculated as: (birthweight-normal birthweight for gestational
age)/SD of normal birthweight. A Swedish reference curve
for normal weight was used [9].
Insulin sensitivity and beta-cell function Insulin sensitivity
was assessed by HOMA of insulin sensitivity (1/HOMA of
insulin resistance [10]) and a modified Matsuda index [11].
Areas under the curve for plasma glucose and serum insulin
were calculated using a trapezoidal method. Beta cell
function (disposition index) was assessed as the product
of insulin secretion (AUCinsulin/AUCglucose) and insulin
sensitivity (modified Matsuda index). Participants with
known type 2 diabetes were excluded from the analysis of
insulin sensitivity, insulin secretion and beta cell function.
Statistical analysis The association between birthweight
and measures of glucose regulation and type 2 diabetes was
investigated in four steps. Model 1 adjusted for age and sex.
Model 2 additionally adjusted for adult BMI. Model 3
additionally adjusted for maternal parity and parental
diabetes status, with missing or ‘unknown’ information on
parental diabetes treated as ‘no diabetes’. Model 4 further
adjusted for socioeconomic factors and lifestyle variables
(physical activity, diet, alcohol consumption and smoking).
Risk of type 2 diabetes was assessed by logistic
regression analysis. Multivariate linear regression analyses
were performed to study the relationship between birth-
weight or prematurity and OGTT-derived measures of
glucose regulation. The outcome variables presented in
Table 1 were loge-transformed to meet the assumption of
normality. Results are in percentage change per 1,000 g
increase in birthweight. We did not use correction for
multiple testing, as our work was based on the predefined
rationale of a potential association between low birthweight
and prematurity, and (1) type 2 diabetes, (2) reduced insulin
sensitivity and (3) beta cell dysfunction as previously
described. SAS version 9.1 (SAS Institute, Cary, NC,
USA) was used for statistical analysis.
Results
In this random sample of Danes, 69% (n=154) of diabetes
cases were screen-detected; the prevalence of type 2
diabetes was 6.5% for men and 3.8% for women.
An increase in birthweight of 1 kg was associated with a
51% (OR 0.49; 95% CI 0.35–0.69; p<0.001) lower risk of
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type 2 diabetes after adjusting for age, sex and BMI
(Table 1). Adjustment for socioeconomic factors and
lifestyle variables did not alter this observation. Supple-
mentary analyses performed only on complete cases or
using simple imputation of missing values for socioeco-
nomic factors and lifestyle variables also did not change the
observations (data not shown).
A 1 SD (2.28 kg/m3) increase in ponderal index was
associated with a 23% (OR 0.77; 95% CI 0.64–0.92;
p<0.01) reduction in the risk of type 2 diabetes as
compared with a 27% (OR 0.73; 95% CI 0.61–0.87;
p<0.001) risk reduction related to an increase in birth-
weight of 1 SD (451 g).
Birthweight was positively related to insulin sensitivity
(Table 1). Despite an inverse relationship between birth-
weight and insulin release, birthweight showed a positive
relationship with beta cell function, reflected by the
disposition index (Table 1).
The participants born prematurely had a higher ponderal
index at birth than SGA participants (Table 2). Despite this
discrepancy, the two groups had similarly increased
prevalence of type 2 diabetes and a similar degree of
post-load hyperglycaemia, hyperinsulinaemia and insulin
resistance. The OR for type 2 diabetes was 1.79 (95% CI
1.17–2.74) for premature participants compared with
participants born at term (SGA+appropriate for gestational
age; p=0.007). Birthweight z-scores, reflecting fetal growth
rates, were not related to risk of type 2 diabetes or measures
of glucose regulation among participants born prematurely
(data not shown).
Discussion
Using a random cohort and a clinical assessment of glucose
regulation and type 2 diabetes, this study demonstrates that
low birthweight and prematurity are associated with
increased risk of type 2 diabetes, supporting a recent
registry-based study [5]. It also documents that low birth-
weight is associated with beta cell dysfunction and reduced
insulin sensitivity, whereas prematurity is associated solely
with attenuated insulin sensitivity.
As for the other end of the birthweight spectrum, elevated
birthweight has been associated with type 2 diabetes in some
Table 1 Risk of type 2 diabetes and percentage differences in OGTT-derived measures of glucose regulation associated with a 1,000 g increase in
birthweight
Variable Model 1 Model 2 Model 3 Model 4
n 3,972 3,972 3,972 3,404
Risk of T2Da 0. 57 (0.41, 0.79)*** 0.49 (0.35, 0.69)*** 0.43 (0.30, 0.62)*** 0.49 (0.33, 0.74)***
OGTTb
n 3,910 3,910 3,910 3,363
Glucose (%)
0 min –0.8 (–1.5, –0.1)* –1.1 (–1.8, –0.4)** –1.2 (–1.9, –0.5)*** –1.0 (–1.7, –0.2)*
30 min –2.2 (–3.6, –0.9)** –2.7 (–3.9, –1.4)*** –2.9 (–4.2, –1.6)*** –2.3 (–3.7, –0.9)***
120 min –5.3 (–7.1, –3.3)*** –6.0 (–7.8, –4.2)*** –6.4 (–8.2, –4.6)*** –5.6 (–7.5, –3.6)***
AUC 0–120 min –2.9 (–4.1, –1.7)*** –3.5 (–4.6, –2.3)*** –3.8 (–4.9, –2.6)*** –3.1 (–4.4, –1.9)***
Insulin (%)
0 min –1.5 (–5.4, 2.6) –4.4 (–7.3, –0.9)* –4.7 (–8.1, –1.2)** –5.4 (–8.9, –1.7)**
30 min –1.7 (–5.6, 2.5) –3.8 (–7.4, 0.0) –2.9 (–6.7, 1.0) –2.6 (–6.5, 1.5)
120 min –16.6 (–21.1, –11.9)*** –19.3 (–23.3, –15.1)*** –19.4 (–23.5, –15.1)*** –18.9 (–23.2, –14.5)***
AUC 0–120 min –5.9 (–9.4, –2.3)** –8.2 (–11.3, –5.1)*** –7.9 (–11.1, –4.7)*** –7.6 (–10.9, –4.3)***
HOMA-IS (%) 2.3 (–2.0, 6.8) 5.7 (1.9, 9.8)** 6.1 (2.1, 10.3)** 6.7 (2.5, 11.1)**
Insulin sensitivity (%) 5.6 (1.5, 10.0)** 9.1 (5.5, 12.8)*** 9.3 (5.6, 13.2)*** 9.1 (5.2, 13.0)***
Disposition index (%) 2.5 (–0.4, 5.4) 3.7 (0.9, 6.5)** 4.6 (1.8, 7.5)** 4.1 (1.1, 7.2)**
Risk of T2D is provided by odds ratio (95% CI). OGTT derived measures of glucose tolerance are provided as mean percentage change (95% CI)
Model 1 was adjusted for age and sex; model 2 was further adjusted for current BMI; model 3 was additionally adjusted for maternal parity, and
maternal and paternal history of diabetes; model 4 was additionally adjusted for socioeconomic status and lifestyle variables (physical activity,
diet, alcohol consumption, smoking)
a Participants born at term with known or screen-detected type 2 diabetes
b Participants with known type 2 diabetes at baseline visit were excluded from OGTT-derived measures of glucose tolerance
*p<0.05; **p<0.01; ***p<0.001
HOMA-IS, HOMA of insulin sensitivity; T2D, type 2 diabetes
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[12] but not all previous studies [1, 2]. The lack of a
significant relation between high birthweight and type 2
diabetes in this study may theoretically be explained by a
low frequency of gestational diabetes among the mothers.
Ponderal index, a measure of thinness at birth, has
previously been proposed to be a stronger predictor of
type 2 diabetes than birthweight [2]. However, our finding
of a quantitatively similar risk of type 2 diabetes for
birthweight and ponderal index neither supports that notion
nor the idea that ponderal index is a superior marker of an
adverse intrauterine environment.
The robustness of our findings is illustrated by the
consistency of the results across the four applied levels of
adjustment. The finding that the associations between
birthweight and risk of type 2 diabetes remained similar
after adjusting for maternal parity and parental diabetes
status (model 3), as well as socioeconomic and lifestyle
factors (model 4), may be explained by the magnitude of
findings for age and BMI, which are included in model 1
and 2, respectively.
Originally, beta cell dysfunction was thought to represent
a key link between low birthweight and the risk of type 2
diabetes [1]. However, subsequent studies reported low
birthweight to be associated with reduced insulin sensi-
tivity rather than decreased insulin secretion [13]. Our
participants with low birthweight had elevated concen-
trations of post-load serum insulin, but when accounting
for insulin sensitivity, their beta cell function was in fact
reduced. The necessity of adjusting for insulin sensitivity
may be particularly important in relatively young study
populations like that of the Inter99 study, as hyper-
insulinaemia and reduced insulin sensitivity precede
pancreatic failure in absolute terms in the natural history
of type 2 diabetes.
Despite less disproportionate fetal growth, reflected by a
higher ponderal index at birth, participants born premature-
ly had a similar reduction of insulin sensitivity as well as a
similarly elevated risk of type 2 diabetes compared with
participants born SGA. Interestingly, no association be-
tween birthweight z scores and type 2 diabetes or other
measures of glucose regulation was observed among the
participants born prematurely, and prematurity was not
associated with reduced beta cell function. Altogether, our
results suggest that the early life programming mechanisms
Table 2 Adult size and glucose regulation in participants born prematurely, SGA or appropriate for gestational age
Characteristic Time of birth p value, premature
Premature Term SGA Term AGA vs SGA vs SGA+AGA
n (men) 160 58 1,928
n (women) 283 88 2,127
Birthweight (g)a 2,555 (403) 2,556 (152) 3,522 (420) 0.99 <0.001
Ponderal index (kg/m3)a 22.8 (2.3) 22.0 (1.9) 24.9 (2.2) <0.001 <0.001
Adult BMI (kg/m2)b 25.8 (4.7) 25.2 (4.1) 26.2 (4.5) 0.17 0.41
Prevalence of T2D (%)c 6.89 6.47 4.82 0.88 0.007
OGTT
Glucose (mmol/l)c
0 min 5.54 (1.01) 5.48 (0.67) 5.51 (0.74) 0.76 0.011
30 min 8.63 (1.82) 8.61 (1.86) 8.62 (1.82) 0.49 0.035
120 min 6.45 (2.43) 6.49 (1.98) 6.14 (2.01) 0.33 0.001
AUC 0–120 min 888 (189) 885 (181) 876 (178) 0.43 0.003
Insulin (pmol/l)c,d
0 min 33 (23–49) 31 (23–47) 35 (23–49) 0.94 0.12
30 min 242 (180–374) 239 (170–371) 234 (165–339) 0.65 0.004
120 min 193 (110–292) 160 (106–282) 149 (91–240) 0.057 <0.001
AUC 0–120 min 22,965 (17,227–35,048) 23,228 (15,825–34,425) 21,930 (15,855–31,050) 0.81 <0.001
HOMA-ISc,d 0.89 (0.56–1.27) 0.94 (0.60–1.28) 0.87 (0.57–1.28) 0.97 0.053
Insulin sensitivityc,d 24.1 (14.6–32.4) 23.3 (16.1–36.2) 24.3 (16.3–34.4) 0.84 <0.001
Disposition indexc,d 629 (471–815) 675 (473–823) 623 (483–801) 0.77 0.80
Unless otherwise indicated, data are means (SD) or medians (interquartile range); participants with known type 2 diabetes at baseline visit were
excluded from OGTT-derived measures of glucose tolerance
a Adjusted for sex; b adjusted for sex and age; c adjusted for sex, age and BMI; d loge transformed prior to statistical analyses between groups
AGA, appropriate for gestational age; T2D, type 2 diabetes
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that mediate the increased risk of type 2 diabetes may be
different for low birthweight and prematurity.
The Inter99 study is based on an age- and sex-stratified
random sample of the population. As in all population-
based studies, it faces selection bias towards more healthy
individuals among participants compared with non-
participants [6]. Moreover, the prevalence of type 2
diabetes was slightly lower among Inter99 participants with
traced midwife records vs those without traced midwife
records [8]. If anything, this selection bias towards
inclusion of the healthiest segment of the Danish middle-
aged population may have led to underestimation of the
reported effects of perinatal factors in the aetiology of
type 2 diabetes.
In conclusion, we found both reduced insulin sensitivity
and beta cell dysfunction to be mediators in the association
between low birthweight and type 2 diabetes. In addition,
prematurity was associated with attenuated insulin sensi-
tivity and type 2 diabetes independently of fetal growth
rate.
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